Hedgehog (Hh) signaling has emerged in recent years as an attractive target for anticancer therapy because its aberrant activation is implicated in several cancers. Major progress has been made in the development of SMOOTHENED (SMO) antagonists, although they have shown several limitations due to downstream SMO pathway activation or the occurrence of drug-resistant SMO mutations. Recently, particular interest has been elicited by the identification of molecules able to hit glioma-associated oncogene (GLI) factors, the final effectors of the Hh pathway, which provide a valid tool to overcome anti-SMO resistance. Here, we review results achieved in developing GLI antagonists, explaining their mechanisms of action and highlighting their therapeutic potential. We also underline the relevance of structural details in their discovery and optimization.
Infante, P., Alfonsi, R., Botta, B., Mori, M., DI MARCOTULLIO, L. (2015). Targeting GLI factors to inhibit the Hedgehog pathway. TRENDS IN PHARMACOLOGICAL SCIENCES, 36(8), 547-558 [10.1016/j.tips.2015.05.006].
Targeting GLI factors to inhibit the Hedgehog pathway
MORI, MATTIA
;
2015-01-01
Abstract
Hedgehog (Hh) signaling has emerged in recent years as an attractive target for anticancer therapy because its aberrant activation is implicated in several cancers. Major progress has been made in the development of SMOOTHENED (SMO) antagonists, although they have shown several limitations due to downstream SMO pathway activation or the occurrence of drug-resistant SMO mutations. Recently, particular interest has been elicited by the identification of molecules able to hit glioma-associated oncogene (GLI) factors, the final effectors of the Hh pathway, which provide a valid tool to overcome anti-SMO resistance. Here, we review results achieved in developing GLI antagonists, explaining their mechanisms of action and highlighting their therapeutic potential. We also underline the relevance of structural details in their discovery and optimization.File | Dimensione | Formato | |
---|---|---|---|
MORI_27-TrendsPharmacologicalSciences_2015 (4).pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.38 MB
Formato
Adobe PDF
|
1.38 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
MORI-Targeting Gli Factors-PostPrint.pdf
accesso aperto
Descrizione: Accepted Manuscript
Tipologia:
Post-print
Licenza:
Creative commons
Dimensione
836.99 kB
Formato
Adobe PDF
|
836.99 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1120428